中药干预肺部疾病/低氧所致肺动脉高压药理作用机制的研究进展  

Research progress on mechanism of traditional Chinese medicine on pulmonary disease/hypoxia induced pulmonary hypertension

作　　者：臧娜 钟秀君[2] 王振伟[2] 方漫兮 汤杰[2] 王庆其[3] ZANG Na;ZHONG Xiujun;WANG Zhenwei;FANG Manxi;TANG Jie;WANG Qingqi(Yueyang Clinical Medical College,Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China;Department of Respiratory,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China;School of Basic Medical Science,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)

机构地区：[1]上海中医药大学岳阳临床医学院,上海200437 [2]上海中医药大学附属岳阳中西医结合医院呼吸内科,上海200437 [3]上海中医药大学基础医学院,上海201203

出　　处：《上海中医药杂志》2022年第9期104-109,共6页Shanghai Journal of Traditional Chinese Medicine

基　　金：上海市卫健委中医药科研项目(2020LP019);上海市卫健委传染病中医药防治能力建设项目(ZYYB-NLPY-13);上海市卫健委治未病技术推广项目(2021);上海中医药大学附属岳阳中西医结合医院中医肺病专科建设项目(YWCZK2020-005)

摘　　要：综述中药干预肺部疾病/低氧所致肺动脉高压药理作用机制的研究进展。研究发现,促进肺血管收缩及肺血管重构有多条分子信号通路,包括低氧诱导因子/瞬时受体电位阳离子通道(TRPC)、丝裂原活化蛋白激酶(MAPK)、Rho蛋白/Rho激酶(Rho/ROCK)、磷脂酰肌醇3-激酶/蛋白激酶B(PI3K/AKT)、骨形态生成蛋白/转化生长因子-β(BMP/TGF-β)和核因子κB(NF-κB)等信号通路,中药复方、中药提取物及中成药可抑制多条信号通路,抑制肺血管重构,延缓肺动脉高压的进程。This paper reviewed the research progress on the mechanism of traditional Chinese medicine on pulmonary disease/hypoxia induced pulmonary hypertension.It was found that there were multiple molecular signaling pathways to promote pulmonary vasoconstriction and pulmonary vascular remodeling,including hypoxia inducible factor/transient receptor potential canonical(TRPC),mitogen activated protein kinases(MAPK),Rho/Rho kinase(ROCK),phosphatidylinositol 3-kinase/protein kinase B(PI3K/AKT),bone morphogenic protein/transforming growth factorβ(BMP/TGF-β),nuclear factor kappa-B(NF-κB).Traditional Chinese medicine compound,traditional Chinese medicine extract and Chinese patent medicine could inhibit multiple signal pathways,inhibit pulmonary vascular remodeling and delay the process of pulmonary hypertension.

关 键 词：肺动脉高压 慢性阻塞性肺疾病 中药 信号通路 药理作用 研究进展 

分 类 号：R285[医药卫生—中药学]